Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 2Phase EARLY_PHASE1 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Carcinoma, Non-Small-Cell Lung 85Neoplasm Metastasis 74Colorectal Neoplasms 74Neoplasms 72Leukemia, Myeloid, Acute 62Breast Neoplasms 54Prostatic Neoplasms 47Multiple Myeloma 47Ovarian Neoplasms 42Pancreatic Neoplasms 41Squamous Cell Carcinoma of Head and Neck 38Melanoma 36Recurrence 33Glioblastoma 33Lung Neoplasms 31Myelodysplastic Syndromes 30Triple Negative Breast Neoplasms 29Lymphoma, Non-Hodgkin 29Advanced Solid Tumors 27Endometrial Neoplasms 26Stomach Neoplasms 24Small Cell Lung Carcinoma 24Carcinoma, Renal Cell 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Brain Neoplasms 22Carcinoma, Hepatocellular 21Sarcoma 19Lymphoma, B-Cell 19Lymphoma, Large B-Cell, Diffuse 18Esophageal Neoplasms 18

Interventions

venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Dexamethasone 1Calcium Dobesilate 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Immunoglobulin Light-chain Amyloidosis × 30 days × Clear all
NCT05839626 2026-05-27

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Sanofi

Phase 1 Terminated
32 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡